Skip to content

ABBV vs JNJ: Dividend Comparison

ABBV$292.85
AbbVie Inc.
Health Care
vs
JNJ$278.81
Johnson & Johnson
Health Care

Dividend data as of

AbbVie Inc. (ABBV) and Johnson & Johnson (JNJ) are both in the Health Care sector, making them natural rivals for dividend investors. ABBV edges ahead on yield at 2.35% versus JNJ's 1.90%. Both stocks show similar dividend growth rates, each around 5.9% over the past five years. ABBV holds the edge in dividend safety with a "Safe" rating. ABBV is a Dividend Contender while JNJ is a Dividend King.

Verdict

Best for Income
ABBV
Higher yield at 2.35%
Best for Growth
ABBV
5yr CAGR of 5.9%
Best for Safety
ABBV
Rated "Safe"

Track ABBV and JNJ in your portfolio

See your real income from both — forward projections, yield on cost, and dividend safety signals. Sync your brokerage free for 30 days, or track holdings manually on the free plan (1 portfolio, 10 holdings).

30-day free brokerage sync trial. No credit card. Then from $9.99/month. Choosing a tracker? See the best dividend trackers compared.

Metric
Price
$292.85
$278.81
Dividend Yield
2.35%
1.90%
Annual Dividend
$6.92
$5.36
5yr Div CAGR
5.9%
5.0%
3yr Div CAGR
5.3%
4.4%
Consecutive Years
12
61
Payout Ratio
1.17%
80.12%
P/E Ratio
—
—
Market Cap
—
—
Income on $10k
$235/yr
$190/yr

Yield Analysis

ABBV
2.35%
JNJ
1.90%

ABBV yields 0.45% more than JNJ. In dollar terms, ABBV pays $6.92/share vs JNJ's $5.36/share annually.

Dividend Growth

ABBV 5yr CAGR
5.9%
decelerating
JNJ 5yr CAGR
5.0%
decelerating

ABBV: Dividend growth is slowing — the 3-year CAGR of 5.3% trails the 5-year rate of 5.9% and the 10-year rate of 11.7%.

JNJ: Dividend growth is slowing — the 3-year CAGR of 4.4% trails the 5-year rate of 5.0% and the 10-year rate of 5.3%.

Dividend Safety

ABBV
Safe
Payout Ratio1%
JNJ
At Risk
Payout Ratio80%

ABBV: The payout ratio of 1% is well within sustainable levels, leaving room for future increases. Earnings cover the dividend 0.8x.

JNJ: The payout ratio of 80% is elevated, which may indicate the dividend could be cut if earnings decline. Earnings cover the dividend 1.2x.

Estimated Annual Dividend Income

Based on current dividend yields. Actual income may vary.

Investment
ABBV
JNJ
$10,000
$235/yr
$190/yr
$50,000
$1,175/yr
$949/yr
$100,000
$2,349/yr
$1,897/yr

What does $10,000 buy in ABBV vs JNJ today?

At $292.85 per share, $10,000 buys about 34.1 shares of AbbVie Inc. (ABBV). Each share pays $6.92 per year in dividends, so the position starts out generating roughly $236 per year — about $20 a month.

At $278.81 per share, $10,000 buys about 35.9 shares of Johnson & Johnson (JNJ). Each share pays $5.36 per year in dividends, so the position starts out generating roughly $192 per year — about $16 a month.

ABBV is the larger income stream from day one: $44 per year more on the same $10,000 invested.

What could $10,000 of ABBV or JNJ income look like in 10 years?

AbbVie Inc. (ABBV) has raised its dividend about 5.9% a year over the past five years. If that pace held, the $235 per year that $10,000 generates today at the current 2.35% yield would reach $416 per year by 2036 — a 4.2% yield on the original cost.

Johnson & Johnson (JNJ) has raised its dividend about 5.0% a year over the past five years. If that pace held, the $190 per year that $10,000 generates today at the current 1.90% yield would reach $308 per year by 2036 — a 3.1% yield on the original cost.

On those trailing rates, ABBV pays more in 2036: $416 versus $308 per year. The projection assumes each five-year growth rate persists and no dividends are reinvested — real payouts will differ.

When would JNJ's dividend growth overtake ABBV's higher yield?

It doesn't, on the trailing numbers. AbbVie Inc. (ABBV) yields more today (2.35% vs 1.90%) and has also grown its dividend at least as fast (5.9% vs 5.0% a year over five years). Unless JNJ accelerates its raises or ABBV stumbles, JNJ never closes the income gap — ABBV wins on both current income and growth.

Can ABBV and JNJ afford their dividends?

AbbVie Inc. (ABBV) earns $5.83 per share against $6.92 paid out in dividends — 0.8x coverage (a 1% payout ratio).

Johnson & Johnson (JNJ) earns $6.59 per share against $5.36 paid out in dividends — 1.2x coverage (a 80% payout ratio).

JNJ's wider coverage leaves more cushion if earnings dip. As a rule of thumb, coverage below about 1.5x (a payout ratio above ~65%) is where a dividend starts to look stretched — worth watching for ABBV if earnings weaken.

Which fits an early-retirement income portfolio better, ABBV or JNJ?

For income you need right now, AbbVie Inc. (ABBV) leads: $100,000 invested today pays about $196 a month at the current 2.35% yield, versus $158 a month from Johnson & Johnson (JNJ) at 1.90%.

ABBV also leads on dividend growth (5.9% vs 5.0% a year over five years), so the trailing numbers favor it on both fronts.

On consistency: ABBV has raised its dividend 12 consecutive years; JNJ has raised its dividend 61 consecutive years.

Many income investors simply hold both — the mix pairs current yield with growth and spreads single-name risk. Whichever way you lean, dividends are never guaranteed; recheck the payout each quarter rather than setting and forgetting.

$10,000 with DRIP: projected annual income

If each holding keeps raising its dividend at its real 5-year rate and every payment is reinvested, a $10,000 position pays $525/yr in ABBV vs $372/yr in JNJ by year 10.

Assumes dividends are reinvested at the current yield and grow at each holding's trailing 5-year dividend CAGR. A projection, not a prediction — no price appreciation modeled.

Frequently Asked Questions

This tool is for educational and informational purposes only and does not constitute investment, financial, tax, or legal advice. Consult a licensed professional before making investment decisions.

Past performance does not guarantee future results. All projections are hypothetical estimates based on user-provided inputs and may differ materially from actual outcomes.

By using this tool you agree to our Terms of Service and Privacy Policy.